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Abstract
Purpose—Anthracycline-induced congestive heart failure (CHF) is a rare but serious toxicity 
associated with this commonly employed anti-cancer therapy. The ability to predict which patients 
might be at increased risk prior to exposure would be valuable to optimally counsel risk to benefit 
ratio for each patient. Herein we present a genome wide approach for biomarker discovery with 
two validation cohorts to predict CHF from adult patients planning to receive an anthracycline.
Experimental Design—We performed a genome wide association study (GWAS) in 
3431patients from the randomized phase III adjuvant breast cancer trial E5103 to identify SNP 
genotypes associated with an increased risk of anthracycline-induced CHF. We further attempted 
candidate validation in two independent phase III adjuvant trials, E1199 and BEATRICE.
Results—When evaluating for cardiologist adjudicated CHF, 11 SNPs had a p-value <10−5 of 
which nine independent chromosomal regions were associated with increased risk. Validation of 
the 2 top SNPs in E1199 revealed one SNP, rs28714259 that demonstrated a borderline increased 
CHF risk (p=0.04, OR=1.9). rs28714259 was subsequently tested in BEATRICE and was 
significantly associated with a decreased left ventricular ejection fraction (p=0.018, OR=4.2).
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Conclusion—rs28714259 represents a validated SNP that is associated with anthracycline-
induced CHF in three independent, phase III adjuvant breast cancer clinical trials.
Keywords
Genome-wide association study; Single nucleotide polymorphisms; Anthracyclines; Congestive 
heart failure
INTRODUCTION
Anthracyclines are a widely used chemotherapeutic class. Despite substantial anti-tumor 
activity, anthracyclines are not without toxicity. Cardiotoxicity, including congestive heart 
failure (CHF), is a dose-limiting side effect (1). Patients that received an anthracycline were 
five-times more likely to develop cardiac symptoms (2). The overall incidence of CHF in 
patients receiving a cumulative dose of 240–360mg/m2 of doxorubicin is 1.7–2.1% (3). The 
optimal definition of cardiac dysfunction is debatable but the most common mode of 
evaluation includes assessment of left ventricular ejection fraction (LVEF). Unfortunately, 
even with expert interpretation, there is variability in its estimation (4).
Anthracycline-induced cardiotoxicity can occur in two distinct forms: acute toxicity that 
develops early and presents as arrhythmias or depressed LVEF, or chronic toxicity, that 
occurs years later. The mechanism of cardiotoxicity is likely related to oxidative stress 
although not completely elucidated (5). Known risk factors for developing clinical 
cardiomyopathy include cumulative dose, age, history of cardiac conditions, hypertension, 
liver disease, and mediastinal radiotherapy (5, 6). Risk of a cardiac event is further increased 
when anthracyclines are combined with other therapies, including trastuzamab (7) and 
bevacizumab (8, 9).
The risk of serious, irreversible cardiac damage has spurred the implementation of 
competing non-anthracycline regimens to obviate this concern (10), although many patients 
still benefit from anthracyclines based on risk or biology. The severity of the side-effect 
necessitates a means to identify high risk patients. Germline genetic biomarkers for CHF 
have been studied, but their ability to reliably predict risk remains unclear as populations 
studied have been heterogeneous and results inconsistent(11–22).
We report a comprehensive evaluation of a large phase III, adjuvant breast cancer trial, 
E5103(9), to identify common single nucleotide polymorphisms (SNPs) that are associated 
with the risk of anthracycline-induced CHF. We performed a genome-wide association study 
(GWAS), which assessed SNPs throughout the genome. Furthermore, we tested our most 
promising SNPs in two independent, randomized phase III trials, E1199 (23) and 
BEATRICE (8), which used a similar anthracycline backbone.
MATERIAL and METHODS
Genome wide association study to identify common variants in ECOG-5103
E5103 Overview—E5103(9) was a phase III adjuvant breast cancer trial that randomized 
4994 patients to doxorubicin (60 mg/m2) and cyclophosphamide (AC) for four cycles, 
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followed by 12 weeks of weekly paclitaxel (Arm A) or to the same chemotherapy with either 
concurrent bevacizumab (Arm B) or concurrent plus sequential bevacizumab (Arm C). 
Patients were allowed to receive AC every two or three weeks at the discretion of the 
treating physician and patients from all arms were scheduled to receive the same cumulative 
dose of doxorubicin Table 1. Analyses were performed across all arms to identify SNPs 
associated with CHF. This correlative study was approved by the Indiana University IRB.
E5103 genotyping and imputation—Due to the availability of germline DNA, 
genotyping was performed at two independent time points in non-overlapping study subsets 
(Figure 1). DNA from an initial 2209 and an additional 1222 patients was genotyped by 
Illumina Genotyping Services using the HumanOmni1-Quad (>1 million SNPs) and the 
HumanOmniExpress (730,525 SNPs) array, respectively. Both sample sets used the Illumina 
BeadChip microarray platform for genotyping and the Illumina GenomeStudio software for 
initial genotyping calls. Of note, SNPs on the HumanOmniExpress were a subset of those on 
the HumanOmni1-Quad. Those SNPs not on the HumanOmniExpress were imputed in the 
second sample subset (Supplemental data).
E5103 case and control definitions for CHF—To be selected for inclusion in E5103, 
patients must have not had a history of clinically significant cardiovascular disease. 
Cardiovascular health was monitored at the start and during the trial by MUGA or 
echocardiograms. Additionally, a cardiac symptoms assessment was performed two years 
post-registration. Cardiac events including: CHF, decrease in LVEF, acute coronary 
syndrome, supraventricular tachycardia and myocardial dysfunction, were diagnosed by a 
cardiologist. Cases to be considered for this correlative study included individuals that had 
centrally reviewed, cardiologist-adjudicated CHF. Controls were strictly defined and 
included patients who did not experience CHF or other reported events of cardiotoxicity 
including: LVEF <50% or drop in LVEF ≥20% from baseline. All controls received the full 
intended dose of AC with no modification.
Statistical analysis—A case-control GWAS was performed in the genetically defined 
European American (EA) subsamples (Supplement Material) to identify SNPs associated 
with the presence or absence of CHF. Age, menopausal status, experimental arm, tumor 
grade, body surface area (BSA), hypertension during therapy and use of anti-hypertension 
medications at baseline or anti-hypertensive therapy added during treatment, were 
considered as covariates in analyses. The p-value threshold was < 0.05 for inclusion of 
covariates in the regression model. SNPs available on the HumanOmni1-Quad array were 
used as the common basis for all statistical analysis. An additive model of SNP effect was 
used when testing all hypotheses. The case-control analysis was conducted using SNPTEST 
v2.4 (https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html). SNP and 
sample quality control (QC) were performed as previously (24) and outlined in 
Supplemental Material.
Validation in E1199
Overview of E1199—E1199(23) was a phase III adjuvant breast cancer trial that 
randomized 5052 patients with node-positive or high-risk, node-negative breast cancer to 
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one of four treatment arms. First, all patients received doxorubicin (60 mg/m2) and 
cyclophosphamide (AC) for four cycles followed by paclitaxel every three weeks for four 
cycles, or paclitaxel weekly for 12 cycles, docetaxel every three weeks for four cycles, or 
docetaxel at weekly for 12 cycles. Tumor derived DNA (formalin fixed paraffin embedded) 
was available from 2906 patients; Figure 1
Candidate validation of top SNPS in E1199—All association results were reviewed 
and priority were given to two SNPs with further evidence of association from other top 
SNPs (p-value <10−5) in linkage disequilibrium (LD) to reduce the risk of false positive 
signals from technical genotyping errors; Figure 2. These two SNPs were genotyped using 
the QuantStudio™ 12K Flex OpenArray® AccuFill™ System (Thermo Fisher Scientific) 
platform.
E1199 case and control definitions for CHF—To be included in E1199, patients must 
have not had a history of myocardial infarction, CHF or significant ischemic or valvular 
heart disease. Cases included patients with reported CHF as defined by the Common 
Toxicity Criteria version 2.0. Raw LVEF data points were not available. Patients were 
considered controls if they had no reported cardiac events and received the full dose of 
intended AC with no dose modification.
Statistical analysis—Comparing cases and controls in the EA subpopulation, logistic 
regression analysis was performed to identify SNPs associated with CHF. Age, BSA and 
treatment arm were considered as covariates. The p-value threshold for significance was set 
at 0.025 after Bonferroni correction was made.
Validation in BEATRICE
Overview of BEATRICE—BEATRICE(8) was a phase III adjuvant breast cancer trial that 
randomized 2591 patients to a minimum of four cycles of standard adjuvant chemotherapy 
(including an anthracycline, taxane or both) at the investigator’s discretion with or without 
bevacizumab for one year. Germline DNA was available from 828 patients; Figure 1.
Candidate SNP validation in BEATRICE—The SNP with borderline association with 
CHF in the E1199 was further tested for association with decreased LVEF in BEATRICE; 
Figure 2. The SNP was genotyped using a TaqMan SNP assay.
BEATRICE case and control definitions for CHF—To be included in BEATRICE, 
patients had a baseline LVEF >55%. In the parent trial, CHF was defined as New York Heart 
Association (NYHA) class III or IV CHF accompanied by a drop in LVEF> 10% to below 
50. There were only 16 cases of NYHA CHF or cardiac death across the parent trial and 
therefore insufficient cases in the cohort of genotyped patients. Thus we enriched statistical 
power by including cases based on low LVEF. Prior to genetic analysis, we selected LVEF 
<45% to be considered an event. Because of inconsistency and inaccuracy of LVEF 
measurement, we did not select <50%, a commonly used criterion for mild dysfunction, to 
minimize false positive events. We also chose 45% based on prior data suggesting that LVEF 
<45% was a strong contributor to future cardiovascular risk (25). Patients were considered 
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controls if they had no reported cardiac events, had no hypertension and received the full 
dose of intended anthracycline without dose modification.
Statistical analysis—Comparing cases and controls in the EA subpopulation, logistic 
regression analysis was performed to identify SNPs associated with decreased LVEF. Age, 
BSA and treatment arm were considered as covariates. Since only one statistical comparison 
was performed, statistical significance was set at a p-value <0.05.
RESULTS
Phenotypes: rate of CHF and clinical predictors
E5103—Of 4033 patients who had available DNA (Figure 1), phenotype data were 
available only from 3394 genotyped patients. In this subgroup, 2% experienced cardiologist-
adjudicated CHF (Table 1). This included 68 cases; 51 EA, 13 African Americans (AA) and 
4 of other race. There was no increased risk across the genetically determined racial groups 
(EA vs. AA vs. other; p-value=0.50). Due to the insufficient number of non-EA cases, 
genetic association analysis was limited to the EA subgroup. Non-genetic demographic 
predictors were compared for the entire group as well as for EAs and AAs separately (Table 
2). Older age was a significant risk factor, with a 43% relative increased risk with each 
decade of life (p=0.009). There was an increased risk in arm C (p=0.04) but not in arm B 
(p=0.87) when compared with arm A. There was an increased risk for patients who were on 
anti-hypertensives at baseline (p=7.2×10−4) but not for those patients who experienced 
therapy-induced hypertension. BSA was not associated with an increased risk in the entire 
cohort (p=0.10) or in EA patients (p=0.79) but was associated with increased risk in AA 
patients (p=0.01).
E1199—Phenotypic data were available from a majority of patients in the parent trial 
(n=4735) as well as the entire genotyped group (n=2906); Figure 1. The risk of CHF was 
1.5% in the parent trial and 1.6% in the genotyped group (Table 1). In the genotyped group, 
there were 47 cases of CHF; 38 among self-defined EA and 7 cases in AA and 2 cases 
among other races. There was no significant increase in risk based on race (EA vs. AA vs. 
other; p-value=0.09). Again, genetic association analyses were limited to the EA subgroup 
due to an insufficient number of non-EA cases. Non-genetic demographic predictors were 
compared for the entire group as well as for EAs and AAs separately (Table 2). Older age 
demonstrated a 39% relative increased risk with each decade of life in the parent population 
(p=0.005). BSA was not associated with risk in the EA population (p=0.61) but a trend for 
increased risk in the AA population (p=0.07). Neither hypertension nor use of anti-
hypertensive data was available in this trial.
BEATRICE—Phenotypic data were available only from the 828 genotyped patients (Figure 
1). In this subgroup of patients, 2.9% experienced a decline in LVEF <45%. This value is 
higher than the 1.6% of population reported to experience NYHA class III or IV CHF in the 
parent trial (8) (Table 1). The subgroup included a total of 24 cases; 21 among self-defined 
EA and the remaining 3 were of other race. There was no increased risk of CHF across the 
self-defined racial groups (EA vs. other; p-value=0.45). Because of insufficient numbers of 
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cases, the genetic association analyses were limited to the EA subgroup. Non-genetic 
demographic predictors were compared for the entire group as well as for EAs and AAs 
separately (Table 2). Older age (p=0.77) and increased BSA (p=0.91) were not associated 
with increased likelihood of decreased LVEF. There was also no increased risk for those 
who experienced significant therapy-induced hypertension (p=0.98).
GWAS results for CHF in E5103
After genotyping and quality control (QC), 810,907 SNPs were used for the GWAS in 
E5103. The strength of association between genotype and CHF (Figure 3) are demonstrated 
in Table 2. 112 SNPs had a p-value <1×10−4 of which 99 were associated with increased risk 
of CHF (OR=1.4–3.7) (Supplemental table 1). Nine independent chromosomal regions 
represented by eleven top SNPs were associated with the risk of CHF (p-value <10−5) and in 
two of the nine regions, there are multiple SNPs that are in LD with top SNPs and also 
provide evidence of association; therefore, the likelihood of a false positive association is 
substantially reduced. One SNP from each of these two regions was selected for validation 
in independent data sets; Figure 2. SNPs previously reported to be associated with 
anthracycline-induced CHF did not provide evidence of association in this study; Table 3.
Evaluation of candidate SNPs in E1199 and BEATRICE
One of the two SNPs genotyped in the E1199, rs28714259, provided evidence of borderline 
association with CHF (p = 0.041, OR = 1.9), whereas the other, rs6883259, was not 
(p=0.50). rs28714259 was subsequently genotyped in BEATRICE and was significantly 
associated with decreased LVEF <45% (p=0.018, OR=4.2) (Figure 2).
DICUSSION
In the present study, we aimed to identify a population at risk for developing CHF from 
anthracyclines using the dose and schedule commonly employed for adult solid tumors. We 
performed a GWAS in a large randomized phase III adjuvant trial. As a follow-up, we 
performed limited genotyping in two large independent phase III adjuvant trials. In total, the 
three large trials enrolled over 12,500 breast cancer patients. All patients in E5103 and 
E1199 received a uniformed dose of doxorubicin (60 mg/m2) and over 95% patients in 
BEATRICE received an anthyracycline. We provide evidence that the SNP, rs28714259, is 
associated with cardiac dysfunction across trials using slightly different phenotype 
definitions. This SNP was among the top SNPs associated with increased risk of CHF 
(OR>1) and also had LD support from another top SNP in our discovery sample set of 
E5103 trial. In all three trials, the A allele was associated with an increased risk of cardiac 
damage: E5103 (OR=2.1; p=9.25×10−6), E1199 (OR=1.9; p=0.04) and BEATRICE 
(OR=4.2; p=0.02).
Age was the most consistent demographic predictor for increased risk as it was associated in 
two of the three trials evaluated here. There was also a correlation between use of anti-
hypertensive agents at baseline in E5103 but an increased risk was not seen for those who 
only had treatment induced hypertension. This would support the notion that underlying and 
potentially long term, cardiovascular disease increased the risk of this toxicity. Unfortunately 
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details of comorbidities were not available for further evaluation. There was also a signal 
that BSA may be an important contributor but was only detected in the AA patients.
Previous studies have evaluated germline predictors. This included evaluation of candidate 
SNPs or gene panels in the metabolism and transport pathway or in the proposed 
mechanistic pathways of anthracycline-induced cardiomyopathy (12–22). Several of these 
studies have demonstrated associations, but none of these candidates were identified in the 
recent GWAS by Aminkeng et al.(11) or in our study (Table 3). Aminkeng et al. focused on 
a pediatric population of EAs with 34 cases of decreased LVEF and 248 controls (11). The 
study identified a SNP in RARG (OR=4.7) that was confirmed in two other independent 
cohorts. Our current study found the opposite effect (decreased rather than increased risk) 
for the RARG SNP (p=4.1×10−6; OR=0.11). There are multiple explanations for the 
incongruence of findings across studies. One likely reason is due to the general 
heterogeneity in studies, including: drug type, drug exposure, phenotype definition and 
population. With regard to the latter, many of the prior studies to date have focused on the 
pediatric patient population.
This study adheres to stringent criteria for biomarker discovery and the correlative study has 
several strengths as outlined (26). First, the discovery cohort was conducted in the context of 
a randomized, phase III adjuvant trial, using a standard number of doses and cycles of 
doxorubicin. The phenotype collection mandated close follow-up of cardiac function with 
serial echocardiography and events defined by cardiologist adjudication based on both 
imaging and clinical picture. The genomic evaluation implemented a comprehensive genome 
wide approach, which allowed for unbiased discovery. The top finding was further supported 
in two independent trials that had the same (E1199) and similar (BEATRICE) doses and 
schedules of anthracycline.
There were also several weaknesses. First, two of the three trials included an experimental 
arm that delivered bevacizumab. Thus, an association with cardiac toxicity due to the 
combination of an anthracycline plus bevacizumab cannot be excluded. This concern is 
substantially minimized as we adjusted for arm of study for both bevacizumab-containing 
trials, E5103 and BEATRICE, and the third trial, E1199, only included anthracycline; with 
the SNP being associated with an increased risk and similar effect size across all three trials. 
Second, the DNA from E1199 was derived from tumor DNA and thus point mutations at the 
SNP site of interest and loss of heterozygosity cannot be excluded. This limitation was 
minimized by assuring meticulous QC of genotyping and that all analyzed SNPs did not 
violate HWE. Finally, we used slightly different definitions of cardiac dysfunction across the 
three trials. E5103 utilized a clinically useful definition of CHF as defined by a centrally 
reviewed, cardiologist adjudication and considered a composite of both symptoms and 
depressed LVEF. E1199 utilized the CTC criteria for CHF and BEATRICE employed the 
NYHA criteria to define cardiac damage. BEATRICE also collected raw LVEF values to 
further refine cases and controls; whereas E1199 did not. Despite the heterogeneity of 
phenotype, the similar results across the three trials strengthen the clinical generalizability of 
this genetic predictor.
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Our top SNP, rs28714259, lies in an intergenic region in chromosome 15 and had LD 
support from nearby SNPs (Figure 3B). There is increasing evidence that intergenic regions 
play an important role in gene expression and regulation through long-range interactions 
(27). Chromatin immunoprecipitation data from the ENCODE project revealed that 
rs28714259 is within the binding site for glucocorticoid receptor (GR) protein (28). Recent 
studies have demonstrated glucocorticoid signaling plays important roles in the structural 
and functional maturation of the fetal heart and in the maintenance of proper cardiac 
function in various animal models (29).
Future confirmatory studies might focus on even less severe phenotypes of cardiac damage, 
as prior data demonstrates that asymptomatic CHF has marked increase 10-year mortality 
(30). Rare toxicities, however, might be best explained by rare variants with large effect size 
and these are not evaluated on current GWAS platforms. Thus additional work evaluating the 
role of rare variants and mechanistic work is warranted and ongoing. The ability to better 
understand which patients might be at higher risk for this serious toxicity is an important 
step toward personalizing therapy and providing better care for our patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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STATEMENT OF CLINICAL RELEVANCE
Anthracyclines are a widely used chemotherapeutic class, but can cause life threatening 
congestive heart failure (CHF). The risk of serious cardiac damage has spurred the 
implementation of competing non-anthracycline regimens; although many patients still 
benefit from anthracyclines based on risk or underlying biology of the tumor. Germline 
genetic biomarkers for CHF have been studied, but their ability to reliably predict risk 
remains unclear as populations studied have been underpowered and heterogeneous, with 
inconsistent results to date. We have identified a SNP, rs28714259 that is associated with 
CHF risk. This SNP was identified through a GWAS from the randomized phase III 
adjuvant breast cancer trial E5103, and was subsequently validated in two independent 
phase III adjuvant breast cancer trials; E1199, and BEATRICE. rs28714259 is associated 
with increased risk of anthracycline induced CHF and might be useful to guide 
appropriate usage of anthracyclines for patients with breast cancer in the curative setting.
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FIGURE 1. 
Consort Diagram. A) E5103-(the genome wide discovery cohort); B) E1199-(first candidate 
SNP validation cohort); C) BEATRICE-(second candidate SNP validation cohort).
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FIGURE 2. 
Flow diagram for candidate SNP selection.
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FIGURE 3. 
CHF GWAS in EA cohort in E5103. A) Manhattan plot for centrally reviewed, cardiologist-
adjudicated congestive heart failure from EA. X-axis indicates the chromosomal position of 
each SNP analyzed; Y-axis denotes magnitude of the evidence for association, shown as –
log10(p-value). SNPs genotyped in the two independent samples are circled; B) p-values 
(−log10) of SNPs near rs28714259 from SNP association analysis with CHF. SNPs are 
colored to reflect their LD with rs28714259.
Schneider et al. Page 16
Clin Cancer Res. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Schneider et al. Page 17
Table 1
Summary of CHF definitions and events across the clinical trials
Trial Definition of CHF Cumulative dose of 
anthracycline Frequency of events Bevacizumab administered
E5103
Centrally reviewed, cardiologist –
adjudicated
(Composite of symptoms and 
lowered LVEF)
All patients received 240 mg/m2 
of doxorubicin 2.0% Two of the three study arms
E1199 Common toxicity criteria v. 2.0 All patients received 240 mg/m
2 
of doxorubicin
Parent trial: 1.5%
GWAS subgroup: 1.6% No
BEATRICE
Parent trial:
NYHA class 3/4 CHF
Current GWAS:
LVEF <45%
94.8% of patients received an 
anthracycline at various doses 
per physician`s choice
Parent trial: 1.6%
GWAS subgroup: 2.9% One of the two study arms
LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; GWAS=genome wide association study
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